Department of Medical Informatics, ERA-EDTA Registry, Academic Medical Center, Universiteit van Amsterdam, Amsterdam, The Netherlands.
Norwegian Renal Registry, Department for Transplant Medicine, Oslo University Hospital, Rikshospitalet, Oslo, Norway.
Nephrol Dial Transplant. 2016 May;31(5):831-41. doi: 10.1093/ndt/gfv327. Epub 2015 Sep 11.
This study examines the time trends in incidence, prevalence, patient and kidney allograft survival and causes of death (COD) in patients receiving renal replacement therapy (RRT) in Europe.
Eighteen national or regional renal registries providing data to the European Renal Association-European Dialysis and Transplant Association Registry between 1998 and 2011 were included. Incidence and prevalence time trends between 2001 and 2011 were studied with Joinpoint and Poisson regression. Patient and kidney allograft survival and COD between 1998 and 2011 were analysed using Kaplan-Meier and competing risk methods and Cox regression.
From 2001 to 2008, the adjusted incidence of RRT rose by 1.1% (95% CI: 0.6, 1.7) annually to 131 per million population (pmp). During 2008-2011, the adjusted incidence fell by 2.2% (95% CI: -4.2, -0.2) annually to 125 pmp. This decline occurred predominantly in patients aged 45-64 years, 65-74 years and in the primary renal diseases diabetes mellitus type 1 and 2, renovascular disease and glomerulonephritis. Between 2001 and 2011, the overall adjusted prevalence increased from 724 to 1032 pmp (+3.3% annually, 95% CI: 2.8, 3.8). The adjusted 5-year patient survival on RRT improved between 1998-2002 and 2003-2007 [adjusted hazard ratio (HRa) 0.85, 95% CI: 0.84, 0.86]. Comparing these time periods, the risk of cardiovascular deaths fell by 25% (HRa 0.75, 95% CI: 0.74, 0.77). However the risk of malignant death rose by 9% (HRa 1.09, 95% CI: 1.03, 1.16) in patients ≥65 years.
This European study shows a declining RRT incidence, particularly in patients aged 45-64 years, 65-74 years and secondary to diabetic nephropathy. Encouragingly, the adjusted RRT patient survival continues to improve. The risk of cardiovascular death has decreased, though the risk of death from malignancy has increased in the older population.
本研究旨在探讨欧洲接受肾脏替代治疗(RRT)患者的发病率、患病率、患者和肾脏移植存活率以及死亡原因(COD)的时间趋势。
纳入了 1998 年至 2011 年间向欧洲肾脏协会-欧洲透析与移植协会登记处提供数据的 18 个国家或地区性肾脏登记处。使用 Joinpoint 和泊松回归分析了 2001 年至 2011 年间的发病率和患病率的时间趋势。使用 Kaplan-Meier 和竞争风险方法以及 Cox 回归分析了 1998 年至 2011 年的患者和肾脏移植存活率和 COD。
2001 年至 2008 年,调整后的 RRT 发病率每年增加 1.1%(95%CI:0.6,1.7),达到每百万人口 131 例(pmp)。2008-2011 年,调整后的发病率每年下降 2.2%(95%CI:-4.2,-0.2),达到每百万人口 125 例。这种下降主要发生在 45-64 岁、65-74 岁的患者中,以及原发性肾脏疾病 1 型和 2 型糖尿病、血管疾病和肾小球肾炎患者中。2001 年至 2011 年间,总体调整后的患病率从 724 例增加到 1032 例(每年增加 3.3%,95%CI:2.8,3.8)。1998-2002 年和 2003-2007 年期间,调整后的 RRT 患者 5 年生存率有所提高[调整后的危险比(HRa)为 0.85,95%CI:0.84,0.86]。与这些时间段相比,心血管死亡的风险降低了 25%(HRa 为 0.75,95%CI:0.74,0.77)。然而,≥65 岁患者的恶性死亡风险增加了 9%(HRa 为 1.09,95%CI:1.03,1.16)。
这项欧洲研究表明,RRT 的发病率呈下降趋势,尤其是在 45-64 岁、65-74 岁的患者中,以及继发于糖尿病肾病的患者中。令人鼓舞的是,调整后的 RRT 患者生存率继续提高。心血管死亡风险有所下降,但老年人群的恶性死亡风险有所增加。